Filter by:
Cardiovascular
November 2026
American Heart Association Scientific Sessions
EDG-15400, A NOVEL SARCOMERE MODULATOR, PREVENTS THE DEVELOPMENT OF DIASTOLIC DYSFUNCTION IN THE ZSF1 RAT MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Cardiovascular
November 2026
American Heart Association Scientific Sessions
EDG-7500, A NOVEL CARDIAC SARCOMERE MODULATOR, PREVENTS LEFT ATRIAL METABOLIC IMPAIRMENT IN YUCATAN MINI-SWINE WITH HYPERTROPHIC CARDIOMYOPATHY CAUSED BY HETEROZYGOUS MYH7 R403Q MUTATION
Cardiovascular
November 2026
American Heart Association Scientific Sessions
EDG-7500, a novel cardiac sarcomere modulator, normalizes left ventricular pre-ejection period inobstructive hypertrophic cardiomyopathy patients through selective reduction of myosin step-size
Muscular Dystrophy
October 2026
2026 American Conference on Pharmacometrics
Population Pharmacokinetic and Pharmacodynamic Analysis of Sevasemten (EDG-5506) in Becker Muscular Dystrophy
Cardiovascular
October 2026
Heart Failure Society of America 2026 Annual Scientific Meeting
EDG-15400, An Investigational Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics, Pharmacodynamics, and Tolerability in Healthy Adult Participants
Cardiovascular
October 2026
Heart Failure Society of America 2026 Annual Scientific Meeting
EQUINOX-HFpEF: A Phase 2 Study of EDG-15400, a Selective Cardiac Sarcomere Modulator, in Adults with Heart Failure with Preserved Ejection Fraction
Cardiovascular
September 2026
JCI Insight
Mechanistic Diversity Within RLC-Dependent Myosin ATPase Inhibitors Differentiates EDG-7500, a ‘Diastolic-selective’ Cardiac Sarcomere Modulator
Cardiovascular
August 2026
ESC Congress 2026
CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
Muscular Dystrophy
July 2026
Journal of Clinical Pharmacology V66(7)
